Merck and Schering-Plough are telling physicians to ignore research showing their jointly marketed cholesterol-drug Vytorin failed to halt progression of artery disease.
It's unlikely they will listen.
Preliminary findings of the study, called Enhance and released in January, drove Vytorin prescriptions down 18 percent and slashed $49 billion from the drugmakers' market value.
In an effort to retain the pill's $2.8 billion in annual sales, Merck and Schering-Plough are doing the unprecedented: discrediting research they funded and helped design.
More
No comments:
Post a Comment